SLG
AXSM icon

Stanley-Laman Group’s Axsome Therapeutics AXSM Stock Holding History

Stanley-Laman Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.26M Buy
19,260
+1,342
+7% +$232K 0.4% 102
2025
Q4 		$3.27M Buy
17,918
+417
+2% +$58.2K 0.42% 93
2025
Q3 		$2.13M Buy
+17,501
New +$1.97M 0.3% 121

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stanley-Laman Group's AXSM Position: Q1 2026 in Review

Stanley-Laman Group increased its Axsome Therapeutics (AXSM) stake by 7.5% in Q1 2026, buying an estimated $232K and bringing the position to 19,260 shares worth $3.26M. The position accounts for 0.4% of the portfolio, ranked #102.

Stanley-Laman Group first reported a position in AXSM in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.27M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Stanley-Laman Group held 19,260 shares of Axsome Therapeutics worth $3.26M as of Q1 2026.
  • Stanley-Laman Group bought 1,342 Axsome Therapeutics shares in Q1 2026, an estimated $232K.
  • Axsome Therapeutics made up 0.4% of Stanley-Laman Group's portfolio in Q1 2026, its #102 holding.
  • Stanley-Laman Group first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Stanley-Laman Group's Axsome Therapeutics position peaked at $3.27M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Stanley-Laman Group's 13F filing for Q1 2026, filed 16 Apr 2026.